Table 2 Illness severity, organ function and inflammatory response at study inclusion
From: Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients
No AKI (n = 72) | AKI (n = 21) | P value | |
|---|---|---|---|
Vasopressors and inotropes | |||
Noradrenaline dose (µg/kg/min) | 0 (0, 0.03) | 0.01 (0, 0.04) | 0.43 |
Adrenaline [n (%)] | 0 (0) | 1 (4.8 %) | 0.23 |
Dobutamine [n (%)] | 1 (1.4 %) | 3 (14.3 %) | 0.04 |
Kidney function | |||
Plasma creatinine [µmol/l] | 82 (69, 96) | 91 (74, 93) | 0.20 |
Δ creatinine [%] | 0 (−12, 18) | 8 (1, 25) | 0.07 |
Early oliguriaa [n (%)] | 6 (8.3 %) | 9 (42.9 %) | 0.001 |
Furosemide dose, mg during previous 24 h | 6 (0, 23) | 0 (0, 35) | 0.93 |
Lung function | |||
Mechanical ventilation [n (%)] | 56 (77.8 %) | 16 (76.2 %) | 1.0 |
FiO2 | 0.35 (0.26, 0.47) | 0.40 (0.30, 0.50) | 0.15 |
PaO2 (kPa) | 10 (9, 11) | 10 (9, 11) | 0.95 |
PaO2/FiO2 ratio | 29 (20, 42) | 26 (18, 35) | 0.31 |
PaCO2 (kPa) | 4.8 (4.3, 5.4) | 4.5 (4.3, 5.0) | 0.12 |
Metabolic | |||
pH | 7.4 (7.3, 7.4) | 7.4 (7.3, 7.4) | 0.64 |
Base excess (mmol/L) | 0.2 (−2.4, 2.8) | −0.3 (−4.1, 1.0) | 0.18 |
Lactate (mmol/L) | 1.6 (1.2, 2.6) | 2.1 (1.2, 2.8) | 0.50 |
Inflammatory response | |||
SIRS [n (%)] | 52 (72.2 %) | 14 (66.7 %) | 0.60 |
SIRS + suspected or confirmed infection [n (%)] | 38 (52.8 %) | 13 (61.9 %) | 0.62 |
White cell count (×109/L) | 11 (8, 15) | 10 (8, 13) | 0.45 |
C-reactive protein (mg/dL) | 74 (26, 181) | 45 (15, 193) | 0.56 |
Plasma biomarkers levels on inclusion | |||
Endostatin (ng/mL) | 31 (23, 40) | 42 (35, 54) | 0.002 |
Cystatin C (mg/dL) | 0.75 (0.64, 1.00) | 1.10 (0.82, 1.40) | 0.02 |
NGAL (ng/mL) | 97 (66, 149) | 133 (67, 180) | 0.29 |